ESMO 2024 Quick Take Insights: A Focus on SPLASH The ESMO 2024 annual meeting in Barcelona, Spain, featured many practice-changing trials and hypothesis-generating data in genitourinary cancer. One of ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...

The authors aimed in this retrospective chart review to evaluate pre-operative urodynamic findings in patients undergoing transobturator male sling (TMS). All TMS performed from 8/2006-6/2012 by a ...

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, ...

Bicycle Therapeutics announced two poster presentations at the 2025 ASCO Annual Meeting, featuring preliminary results from the Phase 1/2 Duravelo-1 study evaluating the Nectin-4-targeting Bicycle® ...

Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with Early-Stage Bladder Cancer Treated with BCG Immunotherapy. July 8, 2025 Health-related quality of life in patients ...

Extending Outcomes in mCRPC: Radioligand Therapy Strategies & Insights from ASCO 2025Sent on 05 June 2025 Receive via e-mail ...

Evan Y. Yu, MD Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

The IMPACT-RCC study 7 evaluated visualization of clear cell RCC lesions in 42 patients with metastatic disease (n = 449 lesions). Patients in this study had a lesion size cutoff of 1 cm (lymph nodes ...